Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Dyne Therapeutics
Related studies linked through entity extraction aliases.
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
- Status
- RECRUITING
- Phase
- PHASE3
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
- Status
- RECRUITING
- Phase
- N/A
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A